Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
76.35
+0.55 (+0.73%)
Official Closing Price
Updated: 4:15 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astrazeneca Plc ADR
< Previous
1
2
3
4
5
6
7
8
9
...
52
53
Next >
3 Stagnating Blue-Chip Stocks Ready to Awaken and Soar
March 20, 2024
These are the stagnating blue-chip stocks to buy at undervalued levels, as they represent fundamentally strong ideas with healthy cash flows.
Via
InvestorPlace
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
March 19, 2024
Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, promising CNS-targeted gene therapies and strategic partnerships driving long-term...
Via
Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq –
March 19, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Fusion Pharma Stock Nearly Doubles After Scoring $2 Billion AstraZeneca Takeover
March 19, 2024
The company is working on radiopharmaceuticals treatments for cancer.
Via
Investor's Business Daily
Why Is Fusion Pharmaceuticals (FUSN) Stock Up 101% Today?
March 19, 2024
Fusion Pharmaceuticals stock is rising higher on Tuesday as AstraZeneca agrees to acquire FUSN for $21 per share with a CVR of $3.
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
March 19, 2024
Pre-market stock movers are worth diving into on Tuesday as we check out all of the hottest news worth reading about this morning!
Via
InvestorPlace
AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer Treatments
March 19, 2024
AstraZeneca to acquire Fusion Pharmaceuticals for $21.00 per share cash plus $3.00 per share CVR upon regulatory milestone achievement, marking a significant $2.4 billion deal. Enhancing cancer...
Via
Benzinga
AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer
March 19, 2024
From
AstraZeneca
Via
Business Wire
AstraZeneca Says Lynparza/Imfinzi Combo Shows Strong Clinical Benefit Vs. Chemotherapy In Endometrial Cancer
March 18, 2024
AstraZeneca's latest analysis on Imfinzi plus chemotherapy followed by Imfinzi plus Lynparza in endometrial cancer. Improved secondary efficacy endpoints in patients with advanced or recurrent...
Via
Benzinga
AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio
March 18, 2024
From
AstraZeneca
Via
Business Wire
7 Mega-Cap Stocks That Can Turn $10,000 Into $1 Million
March 15, 2024
These million dollar mega-cap stocks will continue to produce big winners in 2024 and beyond as they continue to rise.
Via
InvestorPlace
Congressional Scrutiny Intensifies On Chinese Biotech Firms: WuXi AppTec Faces Biotech Exodus
March 14, 2024
Amidst regulatory challenges, WuXi AppTec faces backlash from industry giants. Biotechnology Innovation Organization cuts ties, citing national security concerns. Shares plummet as U.S. bills target...
Via
Benzinga
AstraZeneca Beefs Up Its Endocrine Disease Pipeline With Amolyt Pharma Deal Worth $1.05B
March 14, 2024
AstraZeneca to acquire Amolyt Pharma for up to $1.05 billion, expanding rare disease pipeline with eneboparatide (AZP-3601), a Phase 3 investigational peptide for hypoparathyroidism.
Via
Benzinga
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
March 13, 2024
One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses.
Via
InvestorPlace
What's Going On With Silence Therapeutics Stock Today?
March 13, 2024
Silence Therapeutics reports narrower Q4 loss, data from zerlasiran study, and strengthened cash position. In March 2024, Mallinckrodt notified Silence that they will not pursue further development of...
Via
Benzinga
AstraZeneca announces initiation of THARROS – a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPD
March 13, 2024
From
AstraZeneca
Via
Business Wire
Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach'
March 11, 2024
Goldman Sachs urges investors to diversify geographically due to high concentration in US tech stocks, with Japan, healthcare, and European GRANOLAS highlighted as promising markets.
Via
Benzinga
Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates
March 09, 2024
This week, data from Novo Nordisk’s early-stage study on a new weight loss pill called amycretin showed that it could be more effective than Wegovy. Meanwhile, the FDA approved Johnson & Johnson's lung...
Via
Talk Markets
Exposures
Product Safety
Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029
March 07, 2024
Explore President Biden's plan to expand Medicare drug negotiations, targeting at least 50 drugs annually. Uncover the impact on pharmaceutical profits and the broader health-care policy proposals,...
Via
Benzinga
Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium Epidemic
March 05, 2024
As President Biden prepares for his State of the Union address, he will address issues such as Bidenomics, healthcare, and the US's role in the world.
Via
Benzinga
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
March 02, 2024
Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Meanwhile, AstraZeneca has returned most of the global...
Via
Talk Markets
Got $200? 2 Dividend Stocks to Buy and Hold Forever
March 01, 2024
Trust these two real estate stocks to be attractively priced and proven performers.
Via
The Motley Fool
2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years
March 01, 2024
It will take a lot, but this goal isn't out of reach for these stocks.
Via
The Motley Fool
11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields
February 28, 2024
A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year.
Via
Benzinga
3 Inflation-Resilient Stocks to Weather the Economic Turbulence
February 28, 2024
These are the undervalued inflation-resilient stocks to buy as they represent companies that have strong fundamentals.
Via
InvestorPlace
EXCLUSIVE: Vivani Medical Says Weight Loss/Diabetes Implant At Par With Novo Nordisk's Famed Injectable Wegovy/Ozempic, Animal Studies Shows
February 28, 2024
Vivani Medical unveils preclinical data on NPM-115, a twice-yearly exenatide subdermal implant for weight loss. Achieving a 20% reduction in high-fat diet-induced obese mice, comparable to Novo...
Via
Benzinga
Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors
February 26, 2024
Zealand Pharma's drug showed positive results in 83% of patients in Phase 2 trials for MASH, heating up the race for new obesity drugs and pushing the company's shares 30% higher.
Via
Benzinga
MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA
February 23, 2024
From
AstraZeneca
Via
Business Wire
Move Over Magnificent 7, Say Hello to the GRANOLAS
February 22, 2024
Dive into the compelling world of GRANOLAS stocks: Europe's elite players shaping the future of pharmaceuticals, tech, and consumer goods.
Via
InvestorPlace
Why AstraZeneca Stock Is Trading Higher Tuesday
February 20, 2024
FDA greenlights AstraZeneca's Tagrisso combo for advanced EGFRm NSCLC. FLAURA2 Phase 3 trial results reveal a 38% reduction in progression risk with Tagrisso plus chemo, outperforming monotherapy....
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
...
52
53
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.